# As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

> **NCT04656002** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 43 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Vactosertib

## Key facts

- **NCT ID:** NCT04656002
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10
- **Primary completion:** 2023-12
- **Final completion:** 2024-12
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04656002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04656002, "As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04656002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*